Abstract:Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The development of domain-selective BET inhibitors to separate efficacy and toxicity is urgently needed. Herein, we report a series of furo[3,2-c]pyridin-4(5H)-one derivatives as novel BD2-selective BET inhibitors. The representative compound 8l (XY153) potently bound to BRD4 BD2 with an half-maximum inhibitory concentration (IC50) value of 0.79 nM and displayed 354-fold selectivity over BRD4 BD1. Besides, 8l exhibited 6-fold BRD4 BD2 domain selectivity over other BET BD2 domains. Compound 8l displayed potent antiproliferative activity against multiple tumor cell lines, especially MV4-11 (IC50 = 0.55 nM), while showing weak cytotoxicity against the normal lung fibroblast cell line. It highlights the safety profile of this series of BD2 inhibitors. 8l also demonstrated good metabolic stability in vitro. These data indicate that 8l may serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML).The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00100.Statistics of the data set and structure refinement of 7o, 7u, 8a, 8f, 8k, and 8l (Table S1); Kon, Koff, and Kd values of 8l, 8m, and 3 in the BLI assay (Table S2); inhibition rates of 8j–m, and 3 by alphascreen (Table S3); IC50 values of 8l and 3 in different cell lines (Table S4); structure overlap of 8k with 4 in BRD2 BD2 (Figure S1); dose–response curves of 8l, 8m, and 3 in the BLI assay (Figure S2); binding affinity of compounds 7b, 7r, 7y, 8j, 8k, 8l, 8m, and 1 in the TSA assay (Figure S3); melting curves of 8l, 8m, and 1 in the TSA assay (Figure S4); inhibitory curve of compounds 8l and 3 in different cell lines (Figure S5); 1H NMR and 13C NMR for all final compounds; and HPLC traces for 8h–m (PDF)Molecular formula strings for compounds with associated biological data (CSV)Homology models for the core structure with BRD2 BD2 (PDB)Crystal (X-ray) structure validation reports for compound 7o (PDF)Crystal (X-ray) structure validation reports for compound 7u (PDF)Crystal (X-ray) structure validation reports for compound 8a (PDF)Crystal (X-ray) structure validation reports for compound 8f (PDF)Crystal (X-ray) structure validation reports for compound 8k (PDB: 7WMQ) (PDF)Crystal (X-ray) structure validation reports for compound 8l (PDB: 7WLN) (PDF)Crystal (X-ray) structure validation reports for compound 8k (PDB: 7WJS) (PDF)Crystal (X-ray) structure validation reports for compound 8l (PDB: 7WKY) (PDF)This article has not yet been cited by other publications.

Fragment-based Drug Discovery of 2-Thiazolidinones As Inhibitors of the Histone Reader BRD4 Bromodomain.

Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Development of 4,5-Dihydro-benzodiazepinone Derivatives As A New Chemical Series of Brd4 Inhibitors

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

Development of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As a Novel Chemical Series of BRD4 Inhibitors

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Identification and Characterization of Benzo[d]oxazol-2(3H)-one Derivatives As the First Potent and Selective Small-Molecule Inhibitors of Chromodomain Protein CDYL

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives As Potent and Second Bromodomain (Bd2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors

Discovery of the Natural Product 3',4',7,8-Tetrahydroxyflavone As a Novel and Potent Selective BRD4 Bromodomain 2 Inhibitor.

Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Discovery of Novel Metalloenzyme Inhibitors Based on Property Characterization: Strategy and Application for HDAC1 Inhibitors

Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors

Structure-Based Discovery and Optimization of Furo[3,2- c ]pyridin-4(5 H )-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors

Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization and Biological Evaluation.

Selective inhibition of BET bromodomains